Rheumatologie: Aktuelle Forschung
Offener Zugang
ISSN: 2161-1149 (Printed)
ISSN: 2161-1149 (Printed)
Tracy M Frech and Michael G Spigarelli
Marijuana, the herbal preparation of Cannabis sativa, is used by patients within a medical context as a regulator of neurotransmission for analgesia, antianxiety, antiemetic, and anticonvulsive effects. Medical use of cannabis is limited by potential adverse drug effects, including an increase in heart rate, vasodilation, appetite stimulation, dry mouth, dizziness, and possibly acute psychosis. While cannabis may contain many cannabinoid (tricyclic dibenzopyran) compounds, the psychoactive effects are mediated by Δ9 Tetrahydrocannabinol (THC). The effects of cannabis are primarily exerted through the cannabinoid receptors, CB1 and CB2. Cannabimimetics (commonly referred to as synthetic cannabinoids), a group of compounds encompassing a wide range of chemical structures, have been developed by scientists in order to achieve selectivity toward one or both receptors for improved therapeutic activity with reduced adverse effects. This review discusses the potential therapeutic effect of cannabimimetics as it relates to Systemic Sclerosis (SSc) with an emphasis on possible legal and social concerns.